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Background-—Few studies have examined the relationship of a-linolenic acid (ALA 18:3n-3), an intermediate-chain essential n-3
polyunsaturated fatty acid derived from plants and vegetable oils, with incident atrial ﬁbrillation (AF).
Methods and Results-—The study population included participants from the Cardiovascular Health Study, a community-based
longitudinal cohort of adults aged 65 or older, free of prevalent coronary heart disease and atrial ﬁbrillation. We assessed the
associations of plasma phospholipid and dietary ALA with incident AF using Cox regression. The biomarker analysis comprised a
total of 2899 participants, and the dietary analysis comprised 4337 participants. We found no association of plasma phospholipid
ALA and incident AF. Comparing each of the second, third, and fourth quartiles to the lowest quartile, the hazard ratios for AF were
1.11 (95% CI, 0.90 to 1.37), 1.09 (95% CI, 0.88 to 1.35), and 0.92 (95% CI, 0.74 to 1.15), after adjustment for age, sex, race, clinic,
education, smoking, alcohol, body mass index, waist circumference, diabetes, heart failure, stroke, treated hypertension, and
physical activity (P trend=0.48). When dietary ALA was considered the exposure of interest, results were similar.
Conclusions-—Results from this prospective cohort study of older adults indicate no association of plasma phospholipid or dietary
ALA and incident AF. (J Am Heart Assoc. 2013;2:e003814 doi: 10.1161/JAHA.112.003814)
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A
trial ﬁbrillation (AF) is the most common chronic
arrhythmia in the United States. According to results
from the Framingham Heart Study, the lifetime risk of
developing AF is 26% in men and 23% in women.
1 Risk of
AF increases with age, and the burden of disease is
particularly high among individuals 65 years of age or older.
2
In 2005, there were more than 3 million individuals in the
United States with diagnosed AF, and the prevalence of AF is
projected to reach more than 7.5 million by 2050 as the
population ages.
3 Because AF is associated with signiﬁcant
morbidity, including stroke, heart failure, and mortality, and
there are limited treatment options for AF, primary prevention
of AF is essential.
4–6
Several studies indicate that long-chain n-3 fatty acids
derived from seafood, particularly eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA), are associated with
a lower risk of AF.
7–9 However, little is known about the
relationship of a-linolenic acid (ALA 18:3n-3), an intermediate-
chain essential n-3 polyunsaturated fatty acid derived from
plants and vegetable oils, with incident AF.
8 Major dietary
sources of ALA include ﬂaxseed, canola and soybean oils,
processed foods that contain these oils such as salad
dressing and mayonnaise, and walnuts.
10 Because plant-
derived fatty acids are lower in cost and have greater
worldwide availability than seafood, and at least some
experimental studies suggest possible physiologic beneﬁts
of ALA,
11–13 a better understanding of the relationship of ALA
with incident AF is of public health importance.
Estimation of dietary ALA is challenging because it is
present in many foods and depends on food oil composition.
Plasma phospholipid ALA, an objective biomarker of dietary
From the Cardiovascular Health Research Unit, Departments of Medicine
(A.M.F., D.S.S., B.M.P., R.N.L.), Biostatistics (B.McK.), Health Services (B.M.P.),
and Epidemiology (D.S.S., B.M.P., S.R.H.), University of Washington, Seattle,
WA; Public Health Sciences Division, Fred Hutchinson Cancer Research Center,
Seattle, WA (X.S.); Department of Internal Medicine, University of New Mexico,
Albuquerque, NM (I.B.K.); Departments of Epidemiology (D.M., E.B.R., D.S.),
Biostatistics (D.S.), and Nutrition (D.M., E.B.R., F.M.S.), Harvard School of
Public Health, Boston, MA; Cardiovascular Medicine (D.M., F.M.S.) and
Channing Laboratory (D.M., E.B.R., F.M.S.), Brigham and Women’s Hospital
and Harvard Medical School, Boston, MA.
Reprint requests to: Amanda M. Fretts, PhD, MPH, University of Washington,
1730 Minor Ave, Suite 1360, Seattle, WA 98101. E-mail: amfretts@
u.washington.edu
Received August 6, 2012; accepted December 12, 2012.
ª 2013 The Authors. Published on behalf of the American Heart Association,
Inc., by Wiley-Blackwell. This is an Open Access article under the terms of the
Creative Commons Attribution Noncommercial License, which permits use,
distribution and reproduction in any medium, provided the original work is
properly cited and is not used for commercial purposes.
DOI: 10.1161/JAHA.112.003814 Journal of the American Heart Association 1
ORIGINAL RESEARCHALA that reﬂects both diet and metabolism, is a measure of
circulating ALA over the past 4 to 8 weeks. The purpose of this
study was to examine the association of plasma phospholipid
and dietary ALA with incident AF in the Cardiovascular Health
Study (CHS), a community-based longitudinal cohort of adults
aged 65 or older. We hypothesized that higher levels of plasma
phospholipid and dietary intake of ALA are associated with a
lower risk of AF among older adults.
Methods
Study Population
The CHS is a population-based longitudinal study of cardio-
vascular disease among adults aged 65 years or older from 4
US communities (Forsyth County, NC; Sacramento County,
CA; Washington County, MD; Allegheny County, PA). Details of
the study design and sampling methods have been reported
previously.
14 Medicare eligibility lists were used to randomly
select and enroll ambulatory and noninstitutionalized adults
aged 65 years or older in the study. In 1989–1990, 5201
participants enrolled in the study and an additional 687
participants (predominantly African American) enrolled in
1992–1993. In total, 57% of randomly sampled adults agreed
to participate in the study. Participants were followed by
annual clinic visits with interim phone calls for the ﬁrst 10
years of the study and then by biannual phone contact
thereafter. The institutional review board for each site
approved the study, and written informed consent was
obtained from all participants at enrollment.
For the plasma phospholipid analysis, we excluded partic-
ipants with AF (n=313), those with coronary heart disease
(n=809), and those missing the plasma phospholipid ALA
measure (n=1867) at the time of the 1992–1993 blood draw.
The study population for the analysis comprised 2899 persons
in total. For the dietary ALA analyses, participants with
prevalent AF (n=194), with a history of coronary heart disease
(n=1122), or missing diet measurement (n=235) at the time
of the ﬁrst diet assessment (1989–1990 for the old cohort or
1995–1996 for the new cohort) were excluded from analyses.
The analytic cohort for the dietary ALA analysis comprised the
remaining 4337 participants.
Data Collection
Annual clinic examinations included a standardized interview,
physical examination, laboratory evaluations, and diagnostic
testing, including 12-lead electrocardiograms (ECGs). Infor-
mation regarding medical history, education, smoking, alcohol
consumption, and cardiovascular risk factors was collected at
the interview. Blood samples were collected after a 12-hour
overnight fast and stored at 70°C.
Plasma Phospholipid ALA Measurement
ALA was measured at the Fred Hutchinson Cancer Research
Center (Seattle, WA) using stored samples from 1992–1993.
ALA is expressed as percentage of total fatty acids. Total
lipids were extracted from plasma using the methods of Folch,
as described previously.
15 Phospholipids were separated from
neutral lipids using 1-dimensional thin-layer chromatography.
To prepare fatty acid methyl esters, phospholipid fractions
were directly transesteriﬁed using the Lepage and Roy
method.
16 Gas chromatography was used to separate individual
fatty acids from methyl esters, as previously described (Agilent
5890 Gas Chromatograph ﬂame ionization detector, Agilent
Technologies, Palo Alto, CA; fused silica capillary column SP-2560
[100 m90.25 mm, 0.2 lm], Supelco Belefonte, PA; initial 160°C
for 16 minutes, ramp 3°C/minute to 240°C, hold 15 minutes).
17
Laboratory interassay coefﬁcient of variation was 3.1% for ALA.
18
Dietary ALA Measurement
Food frequency questionnaires (FFQs) were administered in
1989–1990 and 1995–1996 to measure usual dietary intake.
The 1989–1990 FFQ was a picture version of the National
Cancer Registry FFQ and included 99 food items.
19 In 1995–
1996, the Willett 131-item semiquantitative FFQ was admin-
istered.
20 Both these questionnaires have been shown to be
valid and reliable when compared with repeated 24-hour
dietary recalls or 1-week dietary records.
19,20 Each participant
was asked how often, on average, speciﬁed foods had been
consumed during the past year. To obtain a measure of
dietary ALA intake, the frequency response for each food on
the FFQ was multiplied by the dietary ALA content of the food
and then summed for all foods. For the purposes of this
analysis, dietary intake of ALA is expressed as percentage of
total fat. Participants entered the analysis at the time of their
ﬁrst dietary assessment (1989–1990 or 1995–1996). We
cumulatively updated dietary ALA intake among participants
who completed both the 1989–1990 and the 1995–1996 FFQ
and did not develop coronary heart disease (CHD) during 1989–
1996 (n=2436). For participants who developed CHD during
1989–1996 (n=422), only the 1989–1990 measure of dietary
ALA was used for analyses. We chose not to update dietary ALA
intake among participants who developed CHD during follow-up
because diagnosis may have inﬂuenced diet or risk of AF. For
participants who enrolled in the CHS during 1992–1993
(n=350), the 1995–1996 diet measure was used for analyses.
Atrial Fibrillation Assessment
Incident AF, including atrial ﬂutter, was identiﬁed from 12-lead
ECGs performed annually until 1999 or from hospital
discharge diagnoses (ICD-9 codes 427.3, 427.31, 427.32)
21
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subsample of participants in the CHS with a hospital
discharge code for AF indicates that the positive predictive
value of AF identiﬁcation through hospital diagnosis codes is
98.6%.
22 In addition, among 819 CHS participants who
underwent a 24-hour Holter monitor assessment at the
1994–1995 exam, only 1 study participant had sustained or
intermittent AF identiﬁed via the Holter monitor that was not
identiﬁed by either ECG or hospital discharge diagnosis
codes.
7 In total, study participants were followed for up to
16 years for the plasma phospholipid ALA analyses and up to
19 years for the dietary ALA analyses for development of AF.
Statistical Analyses
All statistical analyses were conducted using STATA version
10.0 (Stata Corp, College Station, TX). The associations of
incident AF with plasma phospholipid and dietary ALA were
assessed both linearly and categorically (comparing each of
the top 3 quartiles to the lowest) using multiple Cox
regression models. Death from any cause and loss to
follow-up were considered censoring events. The proportional
hazards assumption for both plasma and dietary ALA was
evaluated using Schoenfeld’s residuals. To avoid false asso-
ciations of nutrients with disease risk because of confounding
by total reported energy intake, all dietary analyses were
adjusted for total energy intake.
23
Two levels of adjustment were used to examine the
associations of ALA with incident AF. Minimal adjustments
included age and sex (and total caloric intake for dietary
analyses) at the time of the plasma phospholipid ALA measure
(or the ﬁrst diet measure for dietary analyses). Additional
adjustments included race (white or African American), clinic
(Bowman Gray, Davis, Hopkins, Pittsburg), education (no high
school, high school/vocational school, college), smoking
(never, past, current), diabetes (yes/no), history of heart
failure (yes/no), history of stroke (yes/no), body mass index
(BMI; kg/m
2), waist circumference (cm), physical activity
(kcal/week), alcohol use (drinks/week), and treated hyper-
tension (yes/no) at the time of the plasma phospholipid ALA
measure (or the ﬁrst diet measure for dietary analyses).
Because linoleic acid (LA), a major dietary polyunsaturated
fatty acid that competes with ALA for elongation into longer-
chain n-3 and n-6 fatty acids, may overwhelm the association
of ALA and AF, we additionally adjusted for LA in sensitivity
analyses. In addition, exposure misclassiﬁcation may increase
with increasing duration of follow-up because of changes in
diet or metabolism over time, and we performed sensitivity
analyses censoring 5 and 10 years after the ﬁrst blood draw.
We examined the potential interaction of ALA with sex and
age to investigate whether these factors modify the associ-
ation of ALA and AF. In addition, because LA may prevent the
elongation/desaturation of ALA into long-chain n-3 fatty
acids,
24 we examined the interaction of LA and ALA on risk of
AF. Because conversion of ALA to EPA and DHA is catalyzed
by the delta-6-desaturase enzyme and genetic variability in
the delta-6-desaturase gene (FADS2) may affect the conver-
sion,
25 we also examined the interaction between the FADS2
genotype and ALA. Wald’s tests were used to evaluate the
statistical signiﬁcance of the multiplicative interaction term
for each factor, with ALA modeled linearly. Because EPA and
DHA have been shown to prevent the desaturation/elongation
of ALA,
26 it is possible that the effect of ALA on AF may differ
among those with high versus low ﬁsh intake. In sensitivity
analyses, we stratiﬁed the analyses at the 25th percentile of
ﬁsh intake (0.55 servings/day).
Missing covariates (<2% for all covariates, except alcohol
intake, for which it was 4.0%) were imputed by multiple
imputations using data on age, sex, smoking, education, race,
BMI, physical activity, self-reported health status, and diabe-
tes at the time of the plasma phospholipid ALA measure (or
the ﬁrst diet measure for dietary analyses).
Results
Among the 2899 CHS participants who made up the analytic
cohort, 63.6% were female, and the median age at the 1989–
1990 examination was 74 years (range, 65 to 98 years).
Plasma phospholipid ALA represented <1% of total fatty acids
(median, 0.14% total fatty acids; range, 0.05% to 0.47% total
fatty acids). Dietary ALA (percent total fat) and plasma
phospholipid ALA were modestly correlated (r=0.18). Plasma
phospholipid ALA was positively correlated with plasma
phospholipid LA (r=0.26) and dietary LA (r=0.15) and
negatively correlated with plasma phospholipid arachidonic
acid (AA) (r=0.37), but it was poorly correlated with plasma
phospholipid EPA, DHA, and DPA (r=0.06) and ﬁsh intake
(r=0.07).
Characteristics of the study participants in 1992–1993
according to quartile of plasma phospholipid ALA are shown in
Table 1. Participants with higher plasma phospholipid ALA
were more likely to be female and white, consumed slightly
more alcohol per week, reported higher levels of education,
had higher levels of plasma phospholipid and reported dietary
LA, were less likely to smoke, take lipid-lowering medication,
or report a history of stroke, heart failure, or diabetes, and had
lower levels of plasma phospholipid AA, BMI, and waist
circumference when compared with participants with lower
levels of plasma phospholipid ALA. There were no differences
in treated hypertension, aspirin use, plasma phospholipid
long-chain n3-fatty acid levels, or reported ﬁsh intake
according to quartile of plasma phospholipid ALA.
During 29 863 person-years of follow-up, there were 707
cases of incident AF. We found no association of plasma
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each of the second, third, and fourth quartiles to the lowest
quartile, the hazard ratios for atrial ﬁbrillation were 1.11 (95%
CI, 0.90 to 1.37), 1.09 (95% CI, 0.88 to 1.35) and 0.92 (95%
CI, 0.74 to 1.15), after adjustment for age, sex, race, clinic,
education, smoking, alcohol, BMI, waist circumference,
diabetes, heart failure, stroke, treated hypertension, and
physical activity (P trend=0.48) (Table 2). Modeling ALA
linearly, additionally adjusting for linoleic acid, or restricting
analyses to the ﬁrst 7 years of follow-up did not materially
alter results (data not shown). There were also no statistically
signiﬁcant interactions between plasma phospholipid ALA and
age, sex, linoleic acid, or FADS genotype when assessing risk
of AF (smallest P for interaction=0.13). When dietary ALA was
considered the exposure of interest, results were similar
(Table 3).
Associations of ALA levels with AF incidence were
generally similar in analyses stratiﬁed by sex (Tables 4 and
5). In addition, the associations of ALA levels with n-6 and n-3
fatty acids (LA, AA, total EPA+DHA+DPA) were similar in men
and women (Table 6). Restricting analyses to subjects with
low ﬁsh consumption (deﬁned as <0.55 servings/week) or
high ﬁsh consumption (≥0.55 servings/week) did not alter
the results.
Discussion
Results from this prospective cohort study of older adults
indicate no association of plasma phospholipid or dietary ALA
and incident AF. To date, only 1 other study has examined the
association of circulating levels of ALA and incident AF in
humans.
8 In that study of Finnish men (mean age at baseline,
53 years), serum ALA was not associated with hospital-
diagnosed AF during 18 years of follow-up. In addition, the
study found no evidence of effect modiﬁcation by ﬁsh intake
(high intake versus low intake). In other words, although the
populations (middle-aged versus elderly) and outcome
Table 1. Characteristics of 2899 Adults Aged 65+ in 1992–1993 According to Plasma Phospholipid ALA
Q1 Q2 Q3 Q4
ALA, % total FA, median 0.10 0.13 0.16 0.21
Range 0.05, 0.11 0.11, 0.14 0.14, 0.18 0.18, 0.47
n 738 711 702 748
Age, y 74.5 (5.0) 74.7 (5.2) 74.7 (5.2) 75.0 (5.2)
Sex, % male 45.1 36.4 34.3 29.5
Race, % white 82.2 86.6 87.5 90.4
Education >high school, % 34.7 34.7 39.5 40.8
Current smoking, % 11.7 11.0 8.0 7.6
Diabetes mellitus, % 17.3 16.7 13.4 10.7
History of stroke, % 5.0 4.6 3.1 2.5
Heart failure, % 2.2 2.7 2.1 1.7
Treated hypertension, % 36.3 38.1 35.0 36.5
Aspirin >2 days in 2 weeks, % 31.1 30.3 31.9 28.6
Lipid-lowering medication, % 8.0 6.2 3.7 (0.2) 4.7 (0.2)
Body mass index, kg/m
2 27.7 (5.1) 27.0 (4.6) 26.6 (4.5) 25.7 (4.4)
Waist circumference, cm 100.1 (13.7) 97.5 (12.8) 96.4 (13.2) 94.1 (13.1)
Physical activity, kcal/week 1462.4 (1712.9) 1373.7 (1650.4) 1338.3 (1564.4) 1615.2 (1916.0)
Alcohol, drinks/week 1.6 (3.9) 1.8 (4.8) 2.2 (5.4) 2.6 (5.3)
Fish intake, servings/week 1.5 (1.4) 1.5 (1.2) 1.5 (1.4) 1.7 (1.5)
Estimated dietary LA, % total fat 0.18 (0.04) 0.19 (0.05) 0.19 (0.05) 0.20 (0.05)
PP EPA+DHA+DPA, % total FA 4.4 (1.2) 4.5 (1.3) 4.5 (1.2) 4.5 (1.2)
PP LA, % total FA 18.8 (2.4) 19.4 (2.4) 19.9 (2.3) 20.6 (2.6)
PP AA, % total FA 12.0 (1.9) 11.4 (1.8) 11.0 (1.7) 10.1 (1.9)
Data presented as mean (SD) or else percentage. ALA indicates a-linolenic acid; FA, fatty acid; LA, linoleic acid; PP, plasma phospholipid; EPA, eicosapentaenoic acid;
DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; AA, arachidonic acid.
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nonhospitalized cases) differed between the 2 studies, the
ﬁndings were consistent and showed no association of ALA
with incident AF in humans.
In our analysis, plasma phospholipid ALA was only
modestly correlated with dietary ALA measured from the
FFQs (r=0.18). This is not surprising, as measurement of
dietary intake of ALA is prone to error because ALA is present
in varying amounts in many foods and oils. In addition, it is
unknown if plasma phospholipid ALA is a good marker of
dietary ALA intake. Because dietary ALA has been shown to
be metabolized shortly after consumption or elongated and
desaturated to form EPA and DHA in limited amounts, ALA
that accumulates in serum may not be a good marker of
dietary ALA intake.
27
Results from observational studies that have examined the
association of dietary intake of ﬁsh or n-3 polyunsaturated
fatty acids (using dietary questionnaires) with incident AF are
conﬂicting.
7,28–31 On the other hand, circulating levels of long-
chain n-3 fatty acids have been consistently associated with a
lower risk of AF.
8,32 In CHS in particular, consumption of
broiled or baked ﬁsh, particularly fatty ﬁsh such as tuna
7 and
plasma phospholipid total long-chain omega-3 fatty acids
32
were both associated with a lower risk of AF. By comparison,
ﬁndings from the CHS indicate that the n-3 fatty acid from
plants, ALA, was not associated with AF risk.
This study has several strengths. The CHS is a population-
based multicenter cohort study in adults aged 65 years or
older—a population at high risk for AF. Unlike the previous
study of ALA and AF, which relied on hospital diagnoses to
capture AF cases, the CHS used both ECGs, performed
annually until 1999, and hospital discharge diagnoses to
identify incident cases. This may lower the possibility of
misclassiﬁcation of AF. Other strengths of this study include
the availability of detailed demographic and clinical data from
the annual study visits to adjust for a variety of potential
confounders and the use of an objective measure of ALA.
Moreover, the use of both plasma phospholipid and diet ALA
measures in this analysis allowed us to explore the associ-
ations of both diet and metabolism (plasma phospholipid ALA)
and diet (dietary ALA) on risk of AF.
This analysis also has limitations. Plasma phospholipid
ALA was only measured at 1 exam (1992–1993), and we
were unable to account for potential changes in circulating
Table 2. Hazard Ratio for Incident Atrial Fibrillation According to Plasma Phospholipid ALA Among 2899 Adults Aged 65+
Quartile
P Value Trend I II III IV
Person-years 7616 7156 7170 7921
Number of cases 178 182 177 170
Hazard ratio (95% CI)
Age- and sex-adjusted 1.0 (ref) 1.15 (0.93 to 1.41) 1.11 (0.90 to 1.37) 0.95 (0.77 to 1.18) 0.60
Multivariate model* 1.0 (ref) 1.11 (0.90 to 1.37) 1.09 (0.88 to 1.35) 0.92 (0.74 to 1.15) 0.48
ALA indicates a-linolenic acid; CI, conﬁdence interval; BMI, body mass index.
*Also adjusts for race, clinic, education, smoking, diabetes, history of heart failure, history of stroke, BMI, waist circumference, physical activity, alcohol use, and treated hypertension.
Table 3. Hazard Ratio for Incident Atrial Fibrillation According to Dietary ALA Intake* Among 4337 Adults aged 65+
Quartile
P Value Trend I II III IV
ALA, % total fat intake, median 1.5 1.9 2.2 2.8
Range 0.8, 1.7 1.8, 2.0 2.1, 2.4 2.5, 4.8
Person-years 11 118 13 362 13 683 11 900
Number of cases 272 277 271 269
Hazard ratio (95% CI)
Age-and-sex-adjusted 1.0 (ref) 0.87 (0.73 to 1.03) 0.89 (0.75 to 1.06) 1.05 (0.88 to 1.25) 0.55
Multivariate model
† 1.0 (ref) 0.87 (0.74 to 1.04) 0.90 (0.75 to 1.07) 1.06 (0.89 to 1.27) 0.48
ALA indicates a-linolenic acid; CI, conﬁdence interval; BMI, body mass index.
*ALA expressed as percentage of total fat.
†Also adjusts for race, clinic, education, smoking, diabetes, history of heart failure, history of stroke, BMI, waist circumference, physical activity, alcohol use, and treated hypertension.
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Hlevels of ALA from ﬂuctuations in diet and metabolism that
occurred during the 16 years of follow-up. However, restrict-
ing analyses to the ﬁrst 5 or 10 years of follow-up did not
materially alter estimated hazard ratios. Intake of dietary ALA
was based on responses to an FFQ, and some participants
might not have accurately recalled dietary information such
as speciﬁc foods consumed, frequency, or portion sizes,
thereby limiting our ability to accurately measure dietary ALA.
We attempted to address potential misclassiﬁcation of diet
by cumulatively updating dietary ALA intake for participants
who had 2 measures of dietary ALA and did not develop CHD
during follow-up. Moreover, because our ﬁndings indicate
that neither diet nor plasma phospholipid ALA is associated
with incident AF, it is unlikely that the null ﬁndings are a
result of error in dietary measurement alone. In total, 24% of
the study population developed AF during follow-up. On the
basis of these numbers of events, we had 80% power to
detect hazard ratios of 0.73 and 0.78 per standard deviation
difference in plasma phospholipid and dietary ALA, respec-
tively. Although we used both ECGs and hospital-discharge
diagnoses to identify incident AF, newly recognized paroxys-
mal AF that was managed in the outpatient setting would be
missed. We adjusted for several factors known to be
associated with ALA and AF, but it is possible that there
may be residual confounding because of other unmeasured or
poorly measured factors associated with ALA and AF. In the
CHS, plasma phospholipid ALA levels were low and very
similar to levels reported in several other cohorts, including
ARIC, CARDIA, MESA, and the Physicians Health Study.
33–35
Finally, our cohort comprised participants aged 65 years or
older, and results may not be generalizable to younger
populations.
Conclusions
Among individuals consuming a typical American diet, neither
ALA consumption (as assessed by FFQ) nor plasma ALA level
was associated with AF. Additional studies are needed to
investigate the association of ALA on AF in populations with
higher ALA intake and different background diets, including
diets low in LA, diets with no ﬁsh intake, and vegetarian diets.
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